dupilumab C??? ??, ??, ??

??

Dupilumab was first approved by the FDA in 2017 for atopic dermatitis. In the United States, subsequent approvals extended to include moderate-to-severe asthma in 2018, based on Phase III trials that confirmed improvements in lung function and reductions in exacerbation frequency. Further, Dupixent was approved for chronic rhinosinusitis with nasal polyposis (CRSwNP), an indication where inflammatory mediators play a key role in symptomatology. More recently, the FDA approved Dupixent for eosinophilic esophagitis in patients 12 years and older, representing a significant advance in managing this debilitating gastrointestinal disorder. Additionally, the drug received approval for prurigo nodularis, thereby expanding its portfolio of applications in chronic dermatological diseases characterized by intense pruritus.

??

Dupilumab, also known as Dupixent, is a treatment for severe atopic eczema.

dupilumab ?? ?? ? ???

???

?? ??

dupilumab ?? ??

???	??	???	??	?? ?	??
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19936	58
TargetMol Chemicals Inc.	+1-781-999-5354; +17819995354	marketing@targetmol.com	United States	32467	58
TargetMol Chemicals Inc.	+1-781-999-5354;	support@targetmol.com	United States	39040	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8615965530500	nickzhang@hangyubiotech.com	China	9946	58
Wuhan Jingkang en Biomedical Technology Co., Ltd	+8613720134139	orders@jknbiochem.com	China	5221	58
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd.	+86-13119157289; +8613119157289	13119157289@163.com	China	996	58
NANJING YINGWEN BIOTECHNOLOGY CO LTD	+8613382787392	sales@aeechem.com	China	10002	58
Yiwu Fengjin Commercial Company	+undefined-86-19164429943 +undefined19164429943	jaspercc0416@163.com	China	1000	58
Suzhou Genelee Bio-Technology Co., Ltd	86-17715515539 17715515539	James@geneleebio.com	China	61	58
Wuhan Sunrise Technology Development Co., Ltd.	27-027-83314682 13554138826	whsrtech@vip.163.com	China	102	62

dupilumab ?? ??: